DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BLUE JET HEALTHCARE LTD (BLUEJET) share price today?

BLUE JET HEALTHCARE LTD (BLUEJET) is trading at ₹584.55 on the NSE, down 0.61% on the day. Source: DocStoX.

What is the PE ratio of BLUE JET HEALTHCARE LTD?

BLUE JET HEALTHCARE LTD has a price-to-earnings (PE) ratio of 33.2 in the Healthcare sector.

What is the market capitalisation of BLUE JET HEALTHCARE LTD?

BLUE JET HEALTHCARE LTD has a market capitalisation of approximately ₹10,145 crore.

BLUE JET HEALTHCARE LTD

BLUEJET·NSE·Healthcare

₹584.55▼ -3.60 (-0.61%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹575.15

₹589.35

52W₹325

₹102837%

Open

₹588.00

High

₹589.35

Low

₹575.15

Prev Close

₹588.15

Volume

4.02L

VWAP

₹581.28

Snapshot

Key fundamentals

Market Cap

₹10,145 Cr

P/E Ratio

33.23Fair

P/B Ratio

7.33

EPS

₹17.59

Book Value

₹78.40

ROE

39.96%Strong

ROCE

40.00%Efficient

Dividend Yield

0.21%

Debt / Equity

0.03Low

Face Value

₹2.00

52W High

₹1027.80

52W Low

₹325.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹234

▼ 60.0%downside

Trading at ₹585 — 60% above our estimate

BearFair valueBull

₹176₹234₹269

/100

Business quality — Solid

Growth 0Profitability 100Efficiency 50Valuation 70

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Strong returns on equity (40%)
Capital is working hard (ROCE 40%)
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

40% ROE fading to 12% over ~10 yrs, on ₹78 book

₹250

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹176

Analyst target

No analyst coverage

—

Blended fair value₹234

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (40%)
Capital is working hard (ROCE 40%)
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

33.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

40.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

40.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.03Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹10,145 Cr

P/B

7.33

EPS

₹17.59

Div Yield

0.21%

What changed

Recent changes

Foreign investors+0.2% stake last quarter
Domestic institutions+4.5% stake last quarter
Promoters-6.66% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 33.2×

Growth

Steady

+10% rev CAGR

Profitability

Excellent

40.0% ROE

Financial health

Rock solid

D/E 0.03

Momentum

N/A

No technicals

Today

Trading activity

Delivery %40.2%

Turnover₹2335.92L Cr

Trades14,294

VWAP₹581.28

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.5%

+13.7%

10Y

—

Profit

+15.7%

+11.8%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 24.0%

Watch-outs

Cons

Stock is trading at 7.96 times its book value
Working capital days have increased from 158 days to 224 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Jul 2026

Promoters trimmed their stake by 6.66 pts; foreign investors bought 0.23 pts; domestic institutions added 4.46 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

73.2%-6.66

Public

17.1%+1.97

FII / FPI

0.6%+0.23

DII

9.1%+4.46

Quarterly trend

Ownership over time

Q2 FY27

Promoter73.15%

FII0.63%

DII9.11%

Public17.11%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions